Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma

摘要: Distinguishing endocervical adenocarcinoma (ECA) from endometrial mucinous (EMMA) is clinically significant in view of the differences their management and prognosis. In this study, we used a panel tumor markers to determine ability distinguish between primary adenocarcinoma. Immunohistochemistry using monoclonal antibodies MUC1 (Ma695), p16, estrogen receptor (ER), progesterone (PR), vimentin, was performed examine 32 cases, including 18 EMMAs 14 ECAs. For MUC1, cases were scored based on percentage staining pattern, apical, apical cytoplasmic (A/C), or negative. cells stained. rest antibodies, semiquantitative scoring system carried out. majority EMMA (14 78%) showed A/C staining, whereas only few ECA (2 14, 14%) positive. The difference expression two groups malignancy statistically (p < 0.001). Staining for p16 positive 10 (71%) 4 (22%) EMMA. Estrogen 3 (21%) 17 (94%) Progesterone 16 (89%) Vimentin 1 (7%) ECA, 9 (50%) EMA, with median range 0 (0–6), 1.5 (0–9) respectively. A immunohistochemical ER, PR, vimentin recommended, when there morphological clinical doubt as site origin.